Navigation Links
LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
Date:6/4/2009

mportant in cancer biology, including genes that regulate angiogenesis, cell metabolism, cell proliferation, cell death (apoptosis) and cell invasion. HIF-1 alpha protein is low in normal cells, but reaches high intracellular concentrations in a variety of cancers and is strongly correlated with poor prognosis and resistance to therapy. Enzon is currently conducting two Phase I studies, evaluating the HIF-1 alpha antagonist in different dosing schedules. The HIF-1 alpha inhibitor is licensed from Santaris Pharma A/S.

The collaboration between Santaris Pharma and Enzon Pharmaceuticals started in 2006 and by 2008 Santaris Pharma had delivered eight LNA based cancer drugs to Enzon Pharmaceuticals of which EZN-2968 was the first. The development of the remaining seven compounds is in progress. Moving forward Enzon is committed to the late stage pre-clinical development of these lead candidates. Santaris Pharma holds the European commercial rights to all the jointly developed cancer compounds.

Santaris Pharma (founded in 2003) is a privately held biopharmaceutical company developing new classes of RNA medicines targeting disease-related mRNAs and miRNAs based on its proprietary LNA Drug Platform. The Company's own research and development activities focus on microRNAs, infectious diseases and metabolic disorders. In addition, Santaris Pharma is leveraging its highly effective and efficient Drug Discovery Engine to generate lead LNA drug candidates against a broad array of disease targets selected by strategic partners. The Company and its corporate partners currently have four compounds in clinical development and a full pipeline in late preclinical development.

    For further information, please contact
    Randi Krogsgaard, Director, Corporate Communications
    Direct phone +45-4517-9879
    Cell: +45-2048-8384
    E-mail: rmk@santaris.com

   
SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
2. LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs
3. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
4. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
5. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
6. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
7. AlphaVax Announces New CMV Advisory Board
8. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
9. Maxygen Announces Hold on MAXY-alpha Development Program
10. VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
11. Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BOTHELL, Wash. , Dec. 24, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced that it will hold its 2015 Annual Meeting ... Because the expected date for the Annual ...
(Date:12/24/2014)... SoundConnect’s 2015 ... introduce cutting edge communication technology, provide continued ... platform upgrades. This webinar series demonstrates online ... their quest to leverage web conferencing’s most ... SoundConnect’s Marketing Manager, Seanna Baumgartner, “Our webinars ...
(Date:12/24/2014)... Tenn. (PRWEB) December 23, 2014 Nashville ... was elected treasurer for the American Society for ... advancing knowledge and research in reproductive medicine. In ... a seat on the executive board and will have ... , Dr. Hill has actively supported ASRM since 1984 ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... the way tiny droplets of fluid dry, Cornell researchers ... nanoscale wires and other devices that ordinarily can be ... guided by molds that "stamp" the desired structures. , ... architectures you want at nanoscale," reported Dan Luo, Cornell ...
... WEBCAST SCHEDULED FOR TUESDAY, OCTOBER 28, SAN DIEGO, ... announced today that the Company will report its third,quarter ... Tuesday,October 28, 2008. Neurocrine will host a live conference ... a Company update Tuesday,afternoon, October 28, 2008 at 5:00 ...
... SGMO ) today announced that the company will,release ... 29,2008, after the market closes. The press release will ... which will be open to the public via,telephone and ... financial results and discuss other business matters., The ...
Cached Biology Technology:Researchers show how to 'stamp' nanodevices with rubber molds 2Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results 2Sangamo BioSciences Announces Third Quarter Conference Call and Webcast 2Sangamo BioSciences Announces Third Quarter Conference Call and Webcast 3
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 /PRNewswire/ ... ) has announced the addition of the ... report to their offering. ... This insight provides an overview of the ... Watermarking aims to control and monitor piracy ...
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... Wisconsin research team, led by John W. Lough, Ph.D., professor ... stem cells (ES cells) in animals can be cultivated to ... to replace tissue damaged as a result of a heart ... or diseased cells in adult tissues has caused extraordinary interest ...
... National Institutes of Health (NIH) announced today a new ... articles resulting from NIH-funded research. The policy ?the first ... release to the public manuscripts from research supported by ... of final publication. , These peer-reviewed, NIH-funded research publications ...
... the process by which a single gene can initiate ... splicing, said Baylor College of Medicine researchers in a ... Molecular Cell. "A major question in biology today is ... 120,000 proteins," said Dr. Bert O'Malley, chair of the ...
Cached Biology News:Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks 2NIH Calls on Scientists to Speed Public Release of Research Publications 2NIH Calls on Scientists to Speed Public Release of Research Publications 3Controlling protein diversity 2
Sf21 cells derived from Spodoptera frugiperda ovarian cells are recommended for high-level production of recombinant proteins. Higher expression levels of some proteins are seen due to the larger ce...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
... SilverQuest Silver Staining Kit is uniquely ... sensitivity with minimal protein modification for ... spectrometry problems associated with traditional silver ... kit because the reagents used do ...
... Medium is formuatled for the growth ... and Sf21 cells. Grace's Insect Mediu, ... it does not contain lactalbumin hydrosylate, ... transfection. Grace's Insect Medium, Supplemented is ...
Biology Products: